Literature DB >> 2830315

Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhythm of ACTH.

R A Salata1, D B Jarrett, J G Verbalis, A G Robinson.   

Abstract

The diurnal response of ACTH release to intravenously administered arginine vasopressin was tested in normal volunteers given consecutively moderate doses of vasopressin every 15 min (0.1, 0.3, 1.0, and 3.0 IU) at 2200 h and again at 0700 h (PM/AM). This protocol was repeated 4 wk later with the times reversed (AM/PM). A dose-related increase in ACTH secretion was observed in all subjects. When the AM response of the AM/PM protocol was compared with the PM response of the PM/AM protocol, the release of ACTH was greater in the morning (P less than 0.05) as evaluated by the following criteria: peak value of ACTH (129.9 +/- 30.4 pg/ml in the AM vs. 57.1 +/- 20.2 in the PM); area under the curve (689 in the AM vs. 259 in the PM); and, sensitivity of the ACTH dose-response curve (first significant increase in ACTH with 1 IU of vasopressin in the AM but not significant even after 3 IU in the PM). In addition, when the AM vasopressin testing followed a previous evening stimulation (PM/AM protocol), there was a blunted ACTH response compared with the AM/PM protocol. Corticotropin-releasing factor (CRF) is probably the major ACTH secretagogue, but since vasopressin acts synergistically with CRF to produce an augmented release of ACTH, we suggest that the ACTH response to administered vasopressin depends upon the ambient endogenous level of CRF. We interpret our data and published data that CRF produces a lesser release of ACTH in the AM as follows: in the morning endogenous CRF is high and administered CRF produces little further release of ACTH, but administered vasopressin acting synergistically with high endogenous CRF causes a greater release of ACTH; conversely, in the evening endogenous CRF is low and administered CRF causes a greater release of ACTH, but vasopressin (a weak secretagogue by itself) gives a low ACTH response. We conclude that vasopressin stimulation of ACTH secretion can be used as an in vivo bioassay of endogenous CRF, and that there is a diurnal rhythm of CRF in hypophyseal portal blood.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2830315      PMCID: PMC442524          DOI: 10.1172/JCI113382

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  Humoral hypothalamic control of anterior pituitary: a study with combined tissue cultures.

Authors:  R GUILLEMIN; B ROSENBERG
Journal:  Endocrinology       Date:  1955-11       Impact factor: 4.736

2.  Diurnal variation in the response of plasma adrenocorticotropin and cortisol to intravenous ovine corticotropin-releasing hormone.

Authors:  G S DeCherney; C R DeBold; R V Jackson; W R Sheldon; D P Island; D N Orth
Journal:  J Clin Endocrinol Metab       Date:  1985-08       Impact factor: 5.958

3.  Augmentation of the response to CRF in man: relative contributions of endogenous angiotensin and vasopressin.

Authors:  S R Milsom; J V Conaglen; R A Donald; E A Espiner; M G Nicholls; J H Livesey
Journal:  Clin Endocrinol (Oxf)       Date:  1985-05       Impact factor: 3.478

4.  Plasma corticotropin, cortisol and growth hormone responses to hypoglycemia in the morning and in the evening.

Authors:  Y Ichikawa; M Nishikai; M Kawagoe; K Yoshida; M Homma
Journal:  J Clin Endocrinol Metab       Date:  1972-05       Impact factor: 5.958

5.  Inhibition of vasopressin-induced ACTH release from the pituitary by glucocorticoids in vitro.

Authors:  N Fleischer; W Vale
Journal:  Endocrinology       Date:  1968-12       Impact factor: 4.736

6.  Effects of a bacterial pyrogen on the pituitary-adrenal axis at various times in the 24 hours.

Authors:  K Takebe; C Setaishi; M Hirama; M Yamamoto; Y Horiuchi
Journal:  J Clin Endocrinol Metab       Date:  1966-04       Impact factor: 5.958

7.  Rapid calculation of radioimmunoassay results.

Authors:  D Rodbard; W Bridson; P L Rayford
Journal:  J Lab Clin Med       Date:  1969-11

8.  Plasma corticosteroid and growth hormone response to lysine-vasopressin in man.

Authors:  J Brostoff; V H James; J Landon
Journal:  J Clin Endocrinol Metab       Date:  1968-04       Impact factor: 5.958

9.  Radioimmunoassay of arginine vasopressin in human plasma.

Authors:  C G Beardwell
Journal:  J Clin Endocrinol Metab       Date:  1971-08       Impact factor: 5.958

10.  Characteristics of the receptors which mediate the stimulation of ACTH secretion by vasopressin in conscious dogs.

Authors:  J Schwartz; I A Reid
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

View more
  15 in total

Review 1.  Autonomic and endocrine control of cardiovascular function.

Authors:  Richard Gordan; Judith K Gwathmey; Lai-Hua Xie
Journal:  World J Cardiol       Date:  2015-04-26

Review 2.  Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin.

Authors:  Timothy G Dinan; Lucinda V Scott
Journal:  J Anat       Date:  2005-09       Impact factor: 2.610

3.  Regulation of Pulsatile and Entropic ACTH Secretion Under Fixed Exogenous Secretagogue Clamps.

Authors:  Ferdinand Roelfsema; Paul Aoun; Paul Y Takahashi; Dana Erickson; Rebecca Yang; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

Review 4.  Psychiatric implications of altered limbic-hypothalamic-pituitary-adrenocortical activity.

Authors:  F Holsboer
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

5.  Local Corticotropin-Releasing Factor Signaling in the Hypothalamic Paraventricular Nucleus.

Authors:  Zhiying Jiang; Shivakumar Rajamanickam; Nicholas J Justice
Journal:  J Neurosci       Date:  2018-01-19       Impact factor: 6.167

6.  Isolated adrenocorticotropic hormone deficiency secondary to hypothalamic deficit of corticotropin releasing hormone.

Authors:  A Velardo; M Pantaleoni; G Zizzo; G Del Rio; F Coletta; C Carani; P Marrama
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

Review 7.  Investigation of the Hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis.

Authors:  Zuleyha Karaca; Ashley Grossman; Fahrettin Kelestimur
Journal:  Rev Endocr Metab Disord       Date:  2021-03-26       Impact factor: 6.514

8.  Safety and Efficacy of Vasopressin After Fontan Completion: A Randomized Pilot Study.

Authors:  Amee M Bigelow; Nancy S Ghanayem; Nathan E Thompson; John P Scott; Laura D Cassidy; Katherine J Woods; Ronald K Woods; Michael E Mitchell; Viktor Hraŝka; George M Hoffman
Journal:  Ann Thorac Surg       Date:  2019-08-07       Impact factor: 5.102

Review 9.  The Hypothalamic-Pituitary Axis and Autoantibody Related Disorders.

Authors:  Cristina Cocco; Carla Brancia; Giulia Corda; Gian-Luca Ferri
Journal:  Int J Mol Sci       Date:  2017-11-03       Impact factor: 5.923

10.  Stress responsiveness of the hypothalamic-pituitary-adrenal axis: age-related features of the vasopressinergic regulation.

Authors:  Nadezhda D Goncharova
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-12       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.